MVP 06 01
Alternative Names: MVdeltaC cancer vaccine - Oncovita; MVP-06-01Latest Information Update: 22 Dec 2023
At a glance
- Originator Oncovita
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 Dec 2023 MVP 06 01 is available for licensing as of 04 Dec 2023. https://www.oncovita.fr/technology-and-science/#Measovir-a-unique-platform
- 04 Dec 2023 Oncovita has patent protection for MeasovirTM platform in USA and Europe, prior to December 2023 (Oncovita website, December 2023)
- 29 Nov 2023 Oncovita plans a phase I/IIa trial for Solid tumours in 2025